For the study, seven osteoporotic postmenopausal patients aged 65-70 received the microchip-based implant. Researchers found the drug and device combination was biocompatible, and patients reported no adverse side effects. The company plans to file for regulatory approval for its first microchip device in 2014.
Related Articles on Medical Devices:
Negotiations Over Medical Device Fees Continue in Congressional Hearing
GHX to Create Industry’s First Implantable Devices Supply Chain Solution for Physician Preference Items
Study: CMS Has Incorporated Evidence-Based Medicine Into Medical Technology Decisions
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
